Neuronox®, Innotox®, and Coretox®

Introduction

Since the initial approval of botulinum toxin for aesthetic indications by the US FDA in 2002, the use of botulinum toxin has been expanded to include various indications in the aesthetic field. It is one of the most frequently performed and minimally invasive aesthetic procedures. In order to cater for the high demand in the market and broaden the choice available to users, there is now a greater variety of botulinum toxin products available around the world than ever before.

Neuronox®, Innotox® and Coretox® are a series of BoNT-A products manufactured by Medytox Inc. ( Fig. 9.1 ). Neuronox® has been registered in 33 countries since its first approval in South Korea in 2006. Neuronox® is approved not only for aesthetic indications, such as glabellar lines and lateral canthal lines, but also for therapeutic indications such as blepharospasm, equinus foot deformity stemming from spasticity in pediatric cerebral palsy, upper limb spasticity after stroke, and cervical dystonia. Innotox®, the first liquid type BoNT-A product, was initially approved in 2013 in South Korea for the treatment of glabellar lines. Coretox®, which is the second BoNT-A product without accessory protein after Xeomin® (Merz Inc., Germany), was first approved in 2016 in South Korea. Coretox® is now approved for glabellar lines and upper limb spasticity after stroke.

This chapter introduces these three different BoNT-A products that come from a single origin, comparing their characteristics and discussing their clinical performances, highlighting their use in Asians.